文献速递胸部肿瘤放疗

局限期小细胞肺癌同步每日一次或每日两次放化疗后的长期结局:CONVERT试验简报

Long-Term Outcomes After Concurrent Once- or Twice-Daily Chemoradiation in Limited-Stage Small Cell Lung Cancer: A Brief Report From the CONVERT Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-03-21

CONVERT是一项国际随机3期试验,比较每日一次放疗(66 Gy/33次/6.5周)与每日两次放疗(45 Gy/30次/3周)同步顺铂/依托泊苷治疗局限期小细胞肺癌。中位随访81.2个月时,两组中位生存分别为25.4个月与30.0个月(HR 1.13,95%CI 0.92-1.38,P=0.247),每日一次组晚期3级食管炎7例(其中4例进展为狭窄或瘘),每日两次组无此类事件。作者结论认为45 Gy每日两次应继续作为标准治疗。

要点

  • 每日一次组与每日两次组中位生存分别为25.4个月与30.0个月,HR 1.13(95%CI 0.92-1.38,P=0.247),未达统计学显著。
  • 每日一次组7例发生3级食管炎(其中4例进展为狭窄或瘘),每日两次组无此类事件。
  • 作者结论认为45 Gy每日两次应继续作为局限期小细胞肺癌的标准治疗。

核心结论

  • CONVERT试验未证明每日一次放疗优于每日两次放疗,且每日一次方案在约80个月随访后毒性略差,作者结论认为45 Gy每日两次应继续作为局限期小细胞肺癌的标准治疗。

研究设计与样本

  • CONVERT(NCT00433563)为国际随机3期临床试验,547例患者按1:1随机分配至每日一次放疗(66 Gy/33次/6.5周)或每日两次放疗(45 Gy/30次/3周),均同步顺铂/依托泊苷。
  • 强制使用三维适形放疗,允许调强放疗,不允许选择性淋巴结照射,预防性颅脑照射由治疗临床医生决定,放疗计划接受中心质量保证。
  • 患者来自73个中心,存活队列(n=164)中位随访81.2个月。

主要发现

  • 每日一次组与每日两次组中位生存分别为25.4个月(95%CI 21.1-30.9)与30.0个月(95%CI 25.3-36.5),HR 1.13(95%CI 0.92-1.38,P=0.247)。
  • 多因素分析中体能状态和肿瘤体积与生存相关。
  • 2017年初始分析之后未发生治疗相关死亡。
  • 晚期毒性方面,每日一次组7例发生3级食管炎(其中4例进展为狭窄或瘘),每日两次组无此类事件;每日一次组与每日两次组分别有2例与3例发生3级肺纤维化。

关键数值与推荐

  • 每日一次放疗方案为66 Gy/33次/6.5周,每日两次放疗方案为45 Gy/30次/3周,均同步顺铂/依托泊苷。

临床怎么用

  • 作者结论认为45 Gy每日两次应继续作为局限期小细胞肺癌的标准治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: CONVERT was a phase 3 international randomized clinical trial comparing once-daily (OD) and twice-daily (BD) radiation therapy (RT). This updated analysis describes the 6.5-year outcomes of these regimens delivered with conformal techniques. METHODS AND MATERIALS: CONVERT (NCT00433563) randomized patients 1:1 between OD RT (66 Gy/33 fractions/6.5 weeks) and BD RT (45 Gy/30 fractions/3 weeks), both delivered with concurrent cisplatin/etoposide. Three-dimensional conformal RT was mandatory, intensity-modulated RT was permitted, and elective nodal irradiation was not allowed. Prophylactic cranial irradiation was delivered at the discretion of treating clinicians. RT treatment planning was subject to central quality assurance. RESULTS: Five hundred forty-seven patients were recruited at 73 centers. The median follow-up for the surviving cohort (n = 164) was 81.2 months. The median survival for the OD and BD arms were 25.4 months (95% CI, 21.1-30.9) and 30.0 months (95% CI, 25.3-36.5; hazard ratio, 1.13; 95% CI, 0.92-1.38; P = .247). Performance status and tumor volume were associated with survival on multivariate analysis. No treatment-related deaths occurred subsequent to the initial analysis performed in 2017. Regarding late toxicity, 7 patients in the OD arm developed grade 3 esophagitis, 4 of which went on to develop stricture or fistulation, compared with no patients in the BD arm. Grade 3 pulmonary fibrosis occurred in 2 and 3 patients in the OD and BD arms, respectively. CONCLUSIONS: As the CONVERT trial did not demonstrate the superiority of OD RT and this regimen had a slightly worse toxicity profile after 80 months of follow-up, 45 Gy BD should remain the standard of care in limited stage small cell lung cancer.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Walls GM, Mistry H, Barlesi F, et al. Long-Term Outcomes After Concurrent Once- or Twice-Daily Chemoradiation in Limited-Stage Small Cell Lung Cancer: A Brief Report From the CONVERT Trial. Int J Radiat Oncol Biol Phys. 2024. PMID: 38521132. doi:10.1016/j.ijrobp.2024.02.063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。